Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Investor Presentation (February 2016)
25 slides from Aurobindo Pharma's investor presentation, February 2016
Slide 1: Investor Presentation February 2016
INVESTOR PRESENTATION February 2016
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Company Overview
Company Overview Among the Top-5 listed pharmaceutical companies from Top 10 Therapy Segments India by sales(1) and market capitalization(2) Category Size (US$ Bn) APL’s presence Oncology 74.5 Well entrenched US portfolio of 387 filed ANDAs including Anti-diabetics 63.6 228 approved; 35 appr
Slide 4: The Journey So Far…
The Journey So Far… Creation of a leading vertically integrated platform Acquired formulations Commencement of export First approval of Controlled Acquired Western European facility in USA and of APIs Substance formulations in commercial operations from Actavis Pharmacin in Netherlands Ini
Slide 5: Our Business Segments
Our Business Segments US EU Ranked 8th* Rx supplier as per Among top 15** Gx companies IMS total prescription dispensed by sales Differentiated pipeline with new Focus markets are France, launches including injectables, Germany, Netherlands, Spain, ophthalmics , speciality products UK, Portu
Slide 6: US Business Overview
US Business Overview Aurobindo USA AuroMedics AuroLife Pharma AuroHealth Natrol Oral Rx Injectables Manufacturing / Pharma OTC Nutraceuticals R&D Cumulative ANDA Filings and Approvals Gross Sales (INR Cr) Tentative Approvals include 21 ANDAs approved under PEPFAR, which are not for commercialization
Slide 7: US: Expanding Portfolio Mix Towards High-value Products
US: Expanding Portfolio Mix Towards High-value Products Portfolio mix is complemented with the introduction of high-value products Future pipeline to include Oncology, Hormones, Depot injections, Inhalers, Patches and Films *Does not include the addressable market of the products approved under PEPF
Slide 8: Natrol
Natrol Amongst the top 20 branded nutraceuticals companies in US Diverse Customer Base with long term relationships with key distribution and retail partners Strong customer partnerships across multiple distribution channels with growth potential within each channel R&D capabilities in new i
Slide 9: EU Business Overview
EU Business Overview France Germany Netherlands Spain UK Portugal Italy Romania Belgium India’s Leading Gx company with strong footprint in Europe; Operations Gross Sales (INR Cr) in 9 countries with full fledged sales force and support infrastructure Presence across Rx, TGx, BGx and Hx segment
Slide 10: EU: Portfolio Mix Across Channels
EU: Portfolio Mix Across Channels Sales split by Channel Sales split by Therapeutic Profile Sales split by Dosage Forms Channels Gx Rx Hx TGx Germany, Spain Geographies All 9 countries 7 countries All 9 countries & Netherlands 757 (primarily 335 (predominantly 757 (including Gx # of Products 34 tabl
Slide 11: ARV Business Overview
ARV Business Overview Focus on global tenders floated by Multi-Lateral Organizations like Gross Sales (INR Cr) Global Fund, USAID/PEPFAR and Country specific MOH tenders; currently caters to 2.2 million HIV+ patients Well integrated supply chain management services and logistics for ARV supplies
Slide 12: Emerging Markets Business Overview
Emerging Markets Business Overview Focus markets include Brazil, South Africa, Ukraine and Mexico Gross Sales (INR Cr) Geographic diversification through expansion into selective markets of Asia Pacific, Africa, Middle East etc Opportunity to Leverage Build branded generics presence Enhance
Slide 13: The Base Business : API
The Base Business : API Gross Sales (INR Cr) Amongst the most vertically integrated generic pharma platforms with API integration for over 75% of its products; offers cost competitiveness and high process chemistry skills coupled with commitment to quality Quality & Reliability of supplies and a
Slide 14: Key Financial Indicators
Key Financial Indicators 9 Mth 9 Mth Key Ratios Mar-13 Mar-14 Mar-15 INR Cr FY14 FY15 FY15 FY16 Net Debt/EBIDTA (x) 3.6 1.7 1.6 Average US$ = INR 60.28 61.04 60.67 64.63 Finance Cost (%) 3.8 2.9 1.9 US 3,403 4,832 3,491 4,478 Net Debt/Equity (x) 1.23 0.95 0.77 EU 672 3,195 2,426 2,285 ROE (%) (Avg)
Slide 15: Consolidated Financial Performance
Consolidated Financial Performance Q3 Q3 Q2 9 Months 9 Months Value INR Cr FY15 FY14 FY16 FY15 FY16 FY16 FY15 Formulations 2,837 2,530 2,681 8,155 7,042 9,559 5,378 API 695 674 691 2,109 2,030 2,706 2,864 Formulations % of sales 80% 79.0% 79.5% 79% 77.6% 77.9% 65% Net Operating Income 3,495 3,166 3,
Slide 16: New Business and Technology Initiatives to Support Growth
New Business and Technology Initiatives to Support Growth PEPTIDES Manufacturing peptides from short to long chain molecules supporting mg to kg scale Highly Experienced team of scientists; developed technologies for over 10 products Two DMFs filed; one to be filed in Q4 FY16 Forward integra
Slide 17: Key Investments for Future Growth
Key Investments for Future Growth Brownfield Expansions ► New dedicated block for lypholized vials at Unit IV (General Injectable facility), India ► New finished dosage formulations blocks at Unit VII (SEZ), India ► New API blocks at Unit XI, India ► Substantial capacity expansion at AuroLife, USA G
Slide 18: Way Forward
Way Forward Market share gain for existing products and introduction of new products (currently 111 ANDAs* Orals under review) Specialty 48* ANDA filings under review for injectables with a pipeline of Oncology, Peptides and Penem USA Expand penetration of existing OTC products and capability to cap
Slide 19: Annexure
Annexure 18
Slide 20: Sales Break-Up
Sales Break-Up FY14 FY15 FY16 INR Bn Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 USA 6.2 7.3 9.3 11.2 11.2 11.7 12.0 13.4 14.3 14.8 15.7 Europe 1.7 1.7 1.5 1.8 8.0 7.7 8.6 7.7 7.4 7.6 7.8 Emerging Market 1.1 0.9 1.3 1.3 1.4 1.6 1.3 1.4 1.7 1.7 1.8 ARV 1.9 2.3 2.2 1.9 2.2 1.4 3.3 2.7 3.0 2.7 3.1 Total Formulati
Slide 21: 5 Year Financial Snapshot
5 Year Financial Snapshot Value INR Bn FY11 FY12 FY13 FY14 FY15 Net sales 41.3 45.7 57.8 80.8 121.1 Dossier Income 2.5 0.6 0.8 0.2 0.1 Net Operating Income 43.8 46.3 58.6 81.0 121.2 Gross margin % of operating income 50.4% 45.5% 48.9% 55.5% 54.6% EBITDA (before Fx and other income) % to Operating 22
Slide 22: Filing details as on 31st Dec 2015
Filing details as on 31st Dec 2015 As at As at As at As at Category Approvals Mar 13 Mar 14 Mar 15 31.12.15 Formulations 228 (FA: 198 TA: US* 269 336 376 387 30) 1,270 Approvals Europe** 1,341 1,542 1,756 2,132 (136 Products) 163 Approvals (81 SA** 314 334 343 361 products) Canada*** 49 72 82 99 82
Slide 23: Extensive Manufacturing Base with High Quality Control and Compliance
Extensive Manufacturing Base with High Quality Control and Compliance Finished Dose Formulations Active Pharma Ingredients Site Product Capabilities Site Product Capabilities Unit III Non antibiotics, ARVs / orals Unit I CVS, CNS, Anti-Allergics, Non-Sterile Unit IV Injectables (Non-antibiotics) Uni
Slide 24: Shareholding Pattern
Shareholding Pattern As on As on As on As on Group 31.03.13 31.03.14 31.03.15 31.12.15 Non-Promoter Holding 46.1% Promoter Group 54.9% 54.6% 54.0% 53.9% FII 16.8% 23.7% 29.6% 28.8% MF / Insurance 13.4% 9.8% 6.2% 6.4% Other Bodies Corporates 5.5% 2.2% 1.6% 2.2% Retail Investors 9.4% 9.7% 8.6% 8.7% To
Slide 25: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Deepika Gupta Padhi Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderab
Aurobindo Pharma — Investor Presentation (February 2016) on 6ix